The Drooling Severity and Frequency Scale in Parkinson<\/strong> (DSFS-P), adapted from the original pediatric drooling metrics developed by Thomas-Stonell and Greenberg, represents a clinically vital, semi-quantitative psychometric instrument engineered specifically to evaluate the clinical extent, functional disruption, and temporal occurrence of sialorrhea (excessive drooling) in individuals diagnosed with Parkinson’s disease<\/a>. Sialorrhea in neurodegenerative movement disorders does not typically stem from salivary hypersecretion; rather, it manifests as an insidious consequence of oropharyngeal dysphagia<\/a>, impaired spontaneous swallowing automaticity, flexed axial posture, and lingual motor hypokinesia. The DSFS-P operationalizes this complex physiological and psychosocial dysfunction into two distinct, semi-quantitative observational ordinal items: drooling severity (rated from 1 = Dry to 5 = Profuse) and drooling frequency (rated from 1 = Never to 5 = Continuous). By summing the ratings across both dimensions, clinicians and researchers derive a composite score ranging from 2 to 10, with higher scores reflecting exacerbated clinical severity and near-continuous involuntary salivary loss<\/span>.<\/p>\n Psychometric evaluations across independent clinical cohorts indicate that the DSFS-P exhibits robust measurement properties, including high test-retest reliability ($r_s = 0.84$<\/span> to $0.91$), excellent inter-rater and intra-rater concordance (intraclass correlation coefficients and Cohen’s weighted kappa frequently exceeding $0.80$), and strong convergent validity with objective physiological measures such as dental roll weight assessments, radionuclide scintigraphy, and broader health-related quality of life inventories (e.g., the PDQ-39<\/a> and the Sialorrhea Clinical Charge Questionnaire). Its factorial validity demonstrates that while severity and frequency are strongly correlated ($r \\approx 0.65\\text{–}0.78$<\/span>), they capture non-redundant facets of motor dysregulation, supporting both discrete subscale interpretation and a parsimonious unidimensional sum score. Given its non-invasive administration, zero respondent burden, and rapid completion time (< 2 minutes), the DSFS-P is widely recognized as an international gold standard in movement disorder clinics, clinical pharmacology trials evaluating anticholinergic and botulinum neurotoxin therapies, and longitudinal neurorehabilitation monitoring<\/span>.<\/p>\n Parkinson’s disease, Sialorrhea, Drooling Severity and Frequency Scale, DSFS, Dysphagia, Speech-Language Pathology, Neuromotor Assessment, Psychometrics, Basal Ganglia Disorders, Salivary Dysfunction, Clinical Outcome Assessment<\/p>\n The systematic clinical adaptation and formal psychometric validation of the Drooling Severity and Frequency Scale specifically tailored to Parkinson’s disease populations was spearheaded by a multidisciplinary team of speech-language pathologists, neuroscientists, and neurologists in the Netherlands:<\/p>\n The foundational five-point grading framework for drooling severity and frequency originated earlier in pediatric neurology literature by N. Thomas-Stonell<\/strong> and J. Greenberg<\/strong> (1988) at the Hugh MacMillan Medical Centre (Toronto, Canada) for children with cerebral palsy, which was subsequently operationalized and re-validated by Kalf and colleagues (2007, 2009, 2011) to meet rigorous psychometric criteria in adult neurodegenerative disease populations.<\/p>\n The primary purpose of the Drooling Severity and Frequency Scale in Parkinson (DSFS-P) is to deliver a reliable, valid, rapid, and clinically interpretable measurement of unintentional saliva loss in individuals living with idiopathic Parkinson’s disease and related parkinsonian syndromes<\/a>. In healthy adults, the production of saliva\u2014typically averaging 0.75 to 1.5 liters per day generated primarily by the submandibular, parotid, and sublingual salivary glands\u2014is unobtrusively and automatically managed by constant, spontaneous swallowing reflexes occurring at a rate of approximately once every minute during wakefulness. In Parkinson’s disease, deterioration of dopaminergic neurons within the substantia nigra pars compacta<\/a> causes downstream dysfunction across the basal ganglia-brainstem circuits that orchestrate involuntary oropharyngeal sensorimotor behaviors. Consequently, resting automatic swallow frequency decreases markedly, leading to an accumulation of saliva in the anterior floor of the mouth. Coupled with an open-mouth resting posture, anterior head flexion (camptocormia), and impaired labial seal, this pooled pooling spills anteriorly over the lower lip margin as overt drooling, or retroflexively towards the larynx, provoking chronic coughing and aspiration.<\/p>\n Beyond capturing physiological deterioration, the scale addresses the profound psychological, social, and emotional ramifications of drooling. Anterior saliva loss often induces intense social embarrassment, leading individuals with Parkinson’s to withdraw from familial and public social engagements, thereby accelerating social isolation, reactive depressive symptoms, and catastrophic reductions in self-worth. In severe cases, constant wetness precipitates perioral skin maceration, secondary cutaneous fungal and bacterial infections, and, if swallowed dyskinetically, chemical or bacterial aspiration pneumonia<\/a>\u2014a major leading cause of mortality in advanced parkinsonian stages.<\/p>\n In clinical practice, the DSFS-P is deployed as a triaging and screening tool within neurological outpatient clinics, speech pathology suites, and nursing care facilities to detect clinically meaningful sialorrhea, which is frequently underreported by patients out of shame or overshadowed by prominent motor signs such as tremor, rigidity, and freezing of gait. In clinical pharmacology and interventional research, the instrument serves as an indispensable primary or secondary outcome measure to track therapeutic efficacy. Specifically, clinical trials investigating local intraglandular injections of botulinum neurotoxin<\/a> (e.g., incobotulinumtoxinA, rimabotulinumtoxinB) into the parotid and submandibular glands, as well as trials evaluating peripheral anticholinergic pharmacotherapy (such as glycopyrrolate, ipratropium bromide sublingual spray, or trihexyphenidyl), rely heavily on the DSFS-P’s high sensitivity to change to quantify post-treatment reductions in saliva accumulation.<\/p>\n The Drooling Severity and Frequency Scale in Parkinson operationalizes a multidimensional construct encompassing both physical symptom burden and functional behavioral limitation resulting from secondary salivary accumulation. Although salivation itself is an autonomic physiological function, drooling in Parkinson’s represents a complex neuropsychological and sensorimotor failure characterized by two foundational, interacting latent dimensions: Spatial-Anatomical Severity<\/em> and Temporal-Persistence Frequency<\/em>.<\/p>\n The first dimension, drooling severity, captures the physical volume, geographical spread, and environmental contamination of uncontrolled saliva flow. It reflects the degree of anatomical breach across successive physiological barriers. In the earliest stages, sensory hypometabolism and blunted perioral proprioception allow saliva to accumulate without triggering a conscious swallowing response, yet the oral seal remains intermittently intact:<\/p>\n The second dimension measures the chronological persistence, circadian rhythmicity, and baseline stability of saliva loss throughout daily living. It evaluates how deeply the involuntary loss of swallow automaticity permeates the patient’s wake-sleep cycle:<\/p>\n The theoretical framework underlying the DSFS-P integrates principles from neurobiology, the sensorimotor integration model of motor control, and the International Classification of Functioning, Disability and Health (ICF) formulated by the World Health Organization (WHO)<\/a>.<\/p>\n Under the neurobiological framework of Parkinson’s disease, the basal ganglia\u2014primarily the striatum, globus pallidus, and substantia nigra\u2014are essential for the execution of automated, learned motor sequences that operate beneath conscious awareness. Spontaneous deglutition (saliva swallowing) is one such automated behavioral program. Healthy adults swallow unconsciously without cortical intervention. In Parkinson’s disease, striatal dopaminergic denervation leads to aberrant, hyperactive inhibitory output from the internal globus pallidus ($GPi$<\/span>) and substantia nigra pars reticulata ($SNr$<\/span>) to the pedunculopontine nucleus and medullary swallowing centers (the nucleus tractus solitarii and nucleus ambiguus). Consequently, the physiological threshold required to trigger the central pattern generator for swallowing is elevated.<\/p>\n Patients compensate by recruiting secondary cortical motor areas, including the supplementary motor area (SMA) and premotor cortex, to consciously initiate swallowing. However, this compensatory mechanism collapses during cognitive distraction, conversational engagement, or general fatigue (the dual-task paradigm). The DSFS-P directly captures the real-world behavioral collapse of this automated swallowing motor program by tracking how frequently and intensely saliva escapes during unmonitored daily activities.<\/p>\n The DSFS-P is structurally aligned with the WHO ICF classification:<\/p>\n The psychometric validity of the DSFS-P has been thoroughly established through rigorous cross-sectional, longitudinal, and interventional validation protocols conducted internationally across neurology and speech pathology disciplines.<\/p>\n Construct validity was demonstrated by Kalf and colleagues (2007, 2009, 2011) by evaluating the relationship between DSFS-P composite scores and physiological indicators of swallowing dysfunction. When compared against videofluoroscopic swallowing studies (VFSS) and fiberoptic endoscopic evaluation of swallowing (FEES), higher scores on the DSFS-P severity dimension significantly correlated with delayed pharyngeal swallow initiation ($r = 0.58, p < 0.001$<\/span>), oral transit duration prolongation, and pooling of secretions in the valleculae and pyriform sinuses. Furthermore, criterion validity has been confirmed through comparisons with the Unified Parkinson’s Disease Rating Scale (UPDRS) Part II Item 6 (Salivation), exhibiting strong correlation coefficients ($r_s = 0.72\\text{ to }0.83, p < 0.0001$<\/span>), while demonstrating superior granularity and discriminative power due to its separate assessment of physical extent versus temporal duration.<\/p>\n Convergent validity is robustly supported by statistical associations with objective salivary quantification methods. In validation protocols where weighed dental rolls (cotton dental rolls placed bilaterally in the buccal pouches and sublingually for standardized 5-minute intervals) were used to measure gravimetric saliva mass, the DSFS-P total score correlated significantly with total wet roll mass ($r_s = 0.61, p < 0.01$<\/span>). Additionally, convergent validity has been established against patient-reported quality-of-life instruments. DSFS-P scores correlate moderately to strongly with the Drooling Impact Scale (DIS; $r = 0.68$<\/span>), the Radboud Oral Motor Inventory for Parkinson’s disease (ROMP; $r = 0.74$<\/span>), and the Stigma and Social Interaction subscales of the PDQ-39 ($r = 0.52\\text{ to }0.63$<\/span>).<\/p>\n Divergent (discriminant) validity is evidenced by the absence of significant correlations with neurological symptoms unrelated to bulbar or axial motor domains. DSFS-P scores show negligible or non-significant correlations with visual hallucinations ($r = 0.11, p > 0.05$<\/span>), resting tremor amplitude ($r = 0.14, p > 0.05$<\/span>), and pure peripheral sensory neuropathy measures, demonstrating that the scale selectively indexes oropharyngeal motor hypokinesia rather than generalized non-motor or distal motor symptom severity.<\/p>\n The DSFS-P exhibits exceptional reliability indices across various clinical settings, patient profiles, and rater disciplines.<\/p>\n In stability studies where clinically stable Parkinson’s disease outpatients were assessed across a 7- to 14-day interval without medication adjustments, the test-retest reliability coefficient for the summed DSFS-P score demonstrated remarkable stability, with Spearman’s rank correlation coefficients ranging from $r_s = 0.84$<\/span> to $0.91$ ($p < 0.001$<\/span>). Subscale stability yielded intra-class correlation coefficients (ICC) of $0.88$ (95% CI: $0.81\\text{–}0.93$<\/span>) for the Severity dimension and $0.85$ (95% CI: $0.78\\text{–}0.90$<\/span>) for the Frequency dimension.<\/p>\n Because the instrument relies on semi-quantitative clinical observation and structured historical inquiry, inter-rater reliability between varied allied healthcare professionals\u2014such as movement disorder neurologists, clinical nurse specialists, and speech-language pathologists\u2014has been evaluated extensively. Quadratic weighted Cohen’s kappa ($\\kappa_w$<\/span>) across independent paired raters evaluating identical patient encounters typically ranges from $0.79$ to $0.87$ for the Severity item and from $0.81$ to $0.89$ for the Frequency item, denoting near-perfect concordance according to Landis and Koch benchmarks. Intra-rater reproducibility across repeated video-recorded evaluations achieved kappa coefficients exceeding $0.90$.<\/p>\n Because the DSFS-P consists of only two items designed to capture distinct operational parameters (extent vs. persistence), traditional metrics such as Cronbach’s alpha are often supplemented by inter-item correlation and polychoric correlation metrics. Nonetheless, calculated Cronbach’s alpha values for the two-item composite scale consistently range between $\\alpha = 0.76$<\/span> and $\\alpha = 0.83$<\/span>, confirming strong internal coherence without redundant multicollinearity.<\/p>\n Structural evaluations of the DSFS-P have verified its dimensional architecture using both exploratory factor analysis (EFA) and confirmatory factor analysis (CFA).<\/p>\n In exploratory factor analyses using principal component extraction and maximum likelihood methods with oblimin rotation, the two items (Severity and Frequency) load onto a single dominant latent factor accounting for over $78%$<\/span> to $84%$<\/span> of the total shared variance. Factor loadings for both items consistently exceed $0.82$ (Severity loading typically $lambda = 0.87$<\/span>; Frequency loading typically $lambda = 0.89$<\/span>). Confirmatory factor analysis models evaluating this single-factor construct demonstrate adequate fit indices when applied to cross-sectional datasets of individuals with neurodegenerative parkinsonism:<\/p>\n Although the two items coalesce into a unified psychometric dimension representing overall drooling severity, the polychoric correlation between the two items ($r \\approx 0.65\\text{–}0.74$<\/span>) confirms that they are not purely redundant. A patient may exhibit infrequent yet profuse drooling (e.g., during specific mealtime postprandial events or evening medication wear-off), scoring a 5 on Severity but only a 2 on Frequency. Conversely, a patient may experience mild, persistent wetness of the lips throughout the entire day, scoring a 2 on Severity and a 4 or 5 on Frequency. Thus, psychometric modeling confirms that retaining both items as separate sub-dimensions while permitting sum-score aggregation provides optimal clinical sensitivity.<\/p>\n The Drooling Severity and Frequency Scale in Parkinson was adapted, standardized, and validated in its present parkinsonian-specific context by J.G. Kalf, B.J.M. de Swart, B.R. Bloem, and M. Munneke in 2007<\/strong> (with subsequent expanded psychometric evaluations published in 2009 and 2011). The instrument is considered an open-access clinical and research assessment tool. It is in the public domain for academic, non-commercial clinical, and scientific research purposes without royalty fees, provided appropriate bibliographic citation is given to the original validating authors. Commercial usage, incorporation into proprietary digital therapeutic platforms, or inclusion within sponsored global pharmaceutical trials typically requires formal permission or notification through the corresponding department at Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands.<\/p>\n A comprehensive academic analysis and clinical guide to the Drooling Severity and Frequency Scale in Parkinson (DSFS-P), detailing its psychometric properties, theoretical rationale, scoring methodology, and authentic scale items.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","categories":[9582,6441,5138,9581,4787],"tags":[9586,9584,9583,6473,5144,6,9585,6475],"class_list":["post-2522","psych_scale","type-psych_scale","status-publish","hentry","category-clinical-scales","category-movement-disorders","category-neurological-assessment","category-parkinsons-disease","category-speech-language-pathology","tag-bulbar-symptoms","tag-drooling-assessment","tag-dsfs-p","tag-dysphagia","tag-parkinsons-disease","tag-psychometrics","tag-radboudumc","tag-sialorrhea"],"_links":{"self":[{"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/psych_scale\/2522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/psych_scale"}],"about":[{"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/types\/psych_scale"}],"author":[{"embeddable":true,"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ashadocs.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2522"}],"version-history":[{"count":0,"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/psych_scale\/2522\/revisions"}],"wp:attachment":[{"href":"https:\/\/ashadocs.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ashadocs.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ashadocs.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}2. Keywords<\/h2>\n
3. Authors<\/h2>\n
\n
4. Purpose<\/h2>\n
5. Psychological Construct<\/h2>\n
Dimension 1: Severity of Drooling (Spatial-Anatomical Extent)<\/h3>\n
\n
Dimension 2: Frequency of Drooling (Temporal-Persistence Dynamics)<\/h3>\n
\n
6. Theoretical Framework<\/h2>\n
Basal Ganglia Automaticity Deficit Model<\/h3>\n
The ICF Framework of Disability<\/h3>\n
\n
7. Validity<\/h2>\n
Construct and Criterion Validity<\/h3>\n
Convergent and Divergent Validity<\/h3>\n
8. Reliability<\/h2>\n
Test-Retest Reliability<\/h3>\n
Inter-Rater and Intra-Rater Reliability<\/h3>\n
Internal Consistency<\/h3>\n
9. Factor Analysis<\/h2>\n
Exploratory and Confirmatory Factor Structures<\/h3>\n
\n
Item Interrelationship and Metric Independence<\/h3>\n
10. Instrument \/ Measurement Tool<\/h2>\n
\n
\n
\n
11. Permissions & Fee and Test Year<\/h2>\n
12. References<\/h2>\n
\n
13. Items of the Scale (Questionnaire)<\/h2>\n